Dynacure Announces First Patient Dosed in Phase 1 / 2 ‘UNITE-CNM’ Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)

siteadmin2020-11-07T02:19:18-08:00March 5, 2020|

Dynacure to Present at 40th Annual Cowen Healthcare Conference

siteadmin2020-11-07T02:20:55-08:00February 26, 2020|

Dynacure’s Chief Scientific Officer, Dr. Belinda Cowling, Receives Irène Joliot-Curie Prize for Women in Business and Technology

siteadmin2020-11-07T02:22:26-08:00November 27, 2019|